The consequences of multimorbidity include polypharmacy and repeated referrals for specialised care, which may increase the risk of adverse drug events (ADEs).AIM: The objective of this study was to analyse the influence of multimorbidity, polypharmacy,  and multiple referrals on the frequency of ADEs, as an indicator of therapeutic safety, in the context of a national healthcare system.